IPO - Profile


We are a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options.

We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to address these diseases. More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$26.41 3,500,000 Positive High 16.17%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • PricewaterhouseCoopers Audit

Deal Highlights

Deal Tracker

IPO Dates

Filing 06 May, 2021

Offer 06 May, 2021

Look Ahead

Lock Up Expiry Nov 06, 2021

IPO Terms

Offer Price $26.41
Offer Size 3M

Market Sentiments

Stock Price